Furmonertinib
Y-2021 AST/zd-0105
Phase 2 small_molecule active
Quick answer
Furmonertinib for Adenocarcinoma of Lung is a Phase 2 program (small_molecule) at Peking University People's Hospital with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Peking University People's Hospital
- Indication
- Adenocarcinoma of Lung
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active